Literature DB >> 17006908

Influence of hepatitis B virus genotypes on the intra- and extracellular expression of viral DNA and antigens.

Masaya Sugiyama1, Yasuhito Tanaka, Takanobu Kato, Etsuro Orito, Kiyoaki Ito, Subrat K Acharya, Robert G Gish, Anna Kramvis, Takashi Shimada, Namiki Izumi, Masahiko Kaito, Yuzo Miyakawa, Masashi Mizokami.   

Abstract

Various genotypes of the hepatitis B virus (HBV) induce liver disease of distinct severity, but the underlying virological differences are not well defined. Huh7 cells were transfected with plasmids carrying 1.24-fold the HBV genome of different genotypes/subgenotypes (2 strains each for Aa/A1, Ae/A2, Ba/B2 and D; 3 each for Bj/B1 and C). HBV DNA levels in cell lysates, determined by Southern hybridization, were the highest for C followed by Bj/Ba and D/Ae (P < .01), and the lowest for Aa (P < .01), whereas in culture media, they were the highest for Bj, distantly followed by Ba/C/D and further by Ae/Aa (P < .01). The intracellular expression of core protein was more than 3-fold lower for Ae/Aa than the others. Hepatitis B e antigen (HBeAg) was excreted in a trend similar to that of HBV DNA with smaller differences. Secretion of hepatitis B surface antigen (HBsAg) was most abundant for Ae followed by Aa, Ba, Bj/C and remotely by D, which was consistent with mRNA levels. Cellular stress determined by the reporter assay for Grp78 promoter was higher for C and Ba than the other genotypes/subgenotypes (P < .01). Severe combined immunodeficiency mice transgenic for urokinase-type plasminogen activator (uPA/SCID), with the liver replaced for human hepatocytes, were inoculated with virions passed in mouse and recovered from culture supernatants. HBV DNA levels in their sera were higher for C than Ae by 2 logs during 4-7 weeks after inoculation. In conclusion, virological differences among HBV genotypes were demonstrated both in vitro and in vivo. These differences may influence HBV infections with distinct genotypes in clinical and epidemiological settings.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17006908     DOI: 10.1002/hep.21345

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  94 in total

1.  Non-nucleoside hepatitis B virus polymerase inhibitors identified by an in vitro polymerase elongation assay.

Authors:  Shogo Nakajima; Koichi Watashi; Kento Fukano; Senko Tsukuda; Kousho Wakae; Hideki Aizaki; Masamichi Muramatsu; Takaji Wakita; Tetsuya Toyoda
Journal:  J Gastroenterol       Date:  2019-11-25       Impact factor: 7.527

2.  Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle.

Authors:  Hironori Nishitsuji; Hiromi Yamamoto; Ritsuko Shiina; Keisuke Harada; Saneyuki Ujino; Kunitada Shimotohno
Journal:  J Vis Exp       Date:  2017-02-01       Impact factor: 1.355

Review 3.  Hepatitis B virus genotypes and variants.

Authors:  Chih-Lin Lin; Jia-Horng Kao
Journal:  Cold Spring Harb Perspect Med       Date:  2015-05-01       Impact factor: 6.915

4.  Peroxiredoxin 1, a Novel HBx-Interacting Protein, Interacts with Exosome Component 5 and Negatively Regulates Hepatitis B Virus (HBV) Propagation through Degradation of HBV RNA.

Authors:  Lin Deng; Xiang Gan; Masahiko Ito; Ming Chen; Hussein H Aly; Chieko Matsui; Takayuki Abe; Koichi Watashi; Takaji Wakita; Tetsuro Suzuki; Toru Okamoto; Yoshiharu Matsuura; Masashi Mizokami; Ikuo Shoji; Hak Hotta
Journal:  J Virol       Date:  2019-03-05       Impact factor: 5.103

5.  CMCdG, a Novel Nucleoside Analog with Favorable Safety Features, Exerts Potent Activity against Wild-Type and Entecavir-Resistant Hepatitis B Virus.

Authors:  Nobuyo Higashi-Kuwata; Sanae Hayashi; Debananda Das; Satoru Kohgo; Shuko Murakami; Shin-Ichiro Hattori; Shuhei Imoto; David J Venzon; Kamalendra Singh; Stefan G Sarafianos; Yasuhito Tanaka; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

Review 6.  The evolution and clinical impact of hepatitis B virus genome diversity.

Authors:  Peter A Revill; Thomas Tu; Hans J Netter; Lilly K W Yuen; Stephen A Locarnini; Margaret Littlejohn
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-05-28       Impact factor: 46.802

7.  Original Research: Analysis of hepatic microRNA alterations in response to hepatitis B virus infection and pegylated interferon alpha-2a treatment.

Authors:  Thananya Jinato; Natthaya Chuaypen; Witthaya Poomipak; Kesmanee Praianantathavorn; Jarika Makkoch; Rattanaporn Kiatbumrung; Kanisa Jampoka; Pisit Tangkijvanich; Sunchai Payungporn
Journal:  Exp Biol Med (Maywood)       Date:  2016-05-04

8.  Identification and characterization of genotype A and D recombinant hepatitis B virus from Indian chronic HBV isolates.

Authors:  Ranjit Chauhan; Syed-Naqui Kazim; Manoj Kumar; Jayashree Bhattacharjee; Narayanasamy Krishnamoorthy; Shiv-Kumar Sarin
Journal:  World J Gastroenterol       Date:  2008-10-28       Impact factor: 5.742

9.  Molecular and phylogenetic analyses suggest an additional hepatitis B virus genotype "I".

Authors:  Hai Yu; Quan Yuan; Sheng-Xiang Ge; Hurng-Yi Wang; Ya-Li Zhang; Qing-Rui Chen; Jun Zhang; Pei-Jer Chen; Ning-Shao Xia
Journal:  PLoS One       Date:  2010-02-19       Impact factor: 3.240

10.  Cell therapy for the diseased liver: from stem cell biology to novel models for hepatotropic human pathogens.

Authors:  Nicolas Brezillon; Dina Kremsdorf; Mary C Weiss
Journal:  Dis Model Mech       Date:  2008 Sep-Oct       Impact factor: 5.758

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.